Add like
Add dislike
Add to saved papers

OS 23-04 A NOVEL HORMONE THERAPY, DROSPIRENONE WITH ESTRADIOL FOR HYPERTENSIVE POSTMENOPAUSAL WOMEN: A SYSTEMIC REVIEW AND META-ANALYSIS.

OBJECTIVE: To assess the efficacy and safety of a novel hormone therapy, drospirenone combined with 17-β-estradiol (DRSP/E2) in postmenopausal hypertensive women.

DESIGN AND METHOD: A systemic literature search of PubMed, Embase, Cochrane Library, Web of Science (up to Oct. 2015) was performed. Studies were screened independently by two researchers according to the inclusion and exclusion criteria which included only the randomized controlled trials (RCT) about the drospirenone with 17-β-estradiol for postmenopausal women with hypertension. The methodological quality was evaluated by Cochrane handbook 5.1.0 and meta-analysis was conducted using RevMan 5.3.0 software.

RESULTS: Five RCTs involved 1121 patients who met the eligibility criteria. Clinical SBP and DBP of DRSP/E2 group reduced by -5.74/-2.61 mmHg (95% CI -7.67 to -3.82, P < 0.00001; 95% CI -3.82 to -1.41, P < 0.00001), which was statistically significant difference compared with placebo group. The meta-analysis of comparative studies found that the 24-h mean systolic blood pressure reduced -5.77 mmHg (95% CI -7.85 to -3.68, P < 0.00001) and the 24-h mean diastolic blood pressure reduced -3.59 mmHg (95% CI -4.92 to -2.27, P < 0.00001). Overall, DRSP/E2 group was superior in reducing clinical blood pressure (BP) and 24-h mean BP. There was no significant change in potassium levels on DRSP/E2 group versus control group, suggesting probability potassium sparing effect of this hormone therapy. The incidences of adverse events were low and similar.

CONCLUSIONS: This meta-analysis demonstrates that a new hormone therapy with aldosterone receptor blocking activity, DRSP/3 mg combined E2/1 mg is effective for lowering clinical BP and 24-h ambulatory blood pressure in postmenopausal hypertensive women. All included participants could well tolerate this hormone therapy. In conclusion, data from recurrent studies support that DRSP/E2 is an effective and safe hormone combination therapy that could be used in postmenopausal hypertension.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app